BioCentury | Sep 19, 2011
Clinical News

BL-5010 regulatory update

BioLineRx said it received European confirmation that BL-5010 for the non-surgical removal of benign skin lesions will be classified as a class IIa medical device. BioLineRx said the classification "considerably" reduces the time and resources...
BioCentury | Jan 10, 2011
Clinical News

BL-5010: Phase I/II data

A single-arm, open-label, German and Dutch Phase I/II trial in 60 patients, showed that BL-1050 met the primary endpoint of safety, with no persistent, irreversible adverse events. A single application of BL-1050 also met the...
BioCentury | Oct 4, 2010

Tel Aviv transit

Tel Aviv transit Functional genomics play Quark Pharmaceuticals Inc. is headed to Tel Aviv to launch its IPO while BioLineRx Ltd. (Tel Aviv:BLRX) is going the other way to add a NASDAQ listing. Quark filed...
BioCentury | Jun 29, 2009
Clinical News

BL-5010: Phase I/II started

BioLineRx began a single-arm, open-label, German and Dutch Phase I/II trial to evaluate BL-5010 in 60 patients. BioLineRx Ltd. (Tel Aviv:BLRX), Jerusalem, Israel Product: BL-5010 Business: Dermatology Molecular target: NA Description: Topical formulation for non-surgical...
BioCentury | Dec 17, 2007
Company News

BioLineRx, Innovative Pharmaceutical Concepts Ltd. deal

Innovative granted BLRX exclusive, worldwide rights to develop and commercialize BL-5010 for non-surgical removal of skin lesions. The topical combination of organic acids is in preclinical testing. Financial terms were not disclosed. BioLineRx Ltd. (Tel...
Items per page:
1 - 5 of 5